Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study,Results at the American Society of Clinical Oncology Annual Meeting ( logo and Cyclacel(R) are trademarks of...)

HOME >> MEDICINE >> TECHNOLOGY

Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study,Results at the American Society of Clinical Oncology Annual Meeting

logo and Cyclacel(R) are trademarks of Cyclacel Pharmaceuticals, Inc.

Risk Factors

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed under "Risk Factors" in the registration statement on Forms S-3 (File No. 333-134945) and S-4 (File No. 333-131225) and in the other reports of Cyclacel filed with the SEC.

Contact

For Investors:
TS Communications Group, LLC
Tara Spiess / Andrea Romstad
914-921-5900
or
For Media:
Feinstein Kean Healthcare
H
'"/>

Page: 1 2 3
Related medicine technology :

1. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
2. Cyclacel Pharmaceuticals to Present Preclinical Data on Sapacitabine and Seliciclib at AACR
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)

Post Your Comments:

(Date:5/20/2013)... -- Uroplasty, Inc. (Nasdaq: UPI ) announced today ... fourth quarter and full year ended March 31, 2013 ... The Company will host a conference call and webcast ... at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). ... dial 888-549-7750, no passcode is necessary. To access the ...

(Date:5/20/2013)... , May 20, 2013 /PRNewswire-iReach/ -- It is no ... one third being overweight or obese gyms and supplement companies ... time the condition is primarily related to dietary issues and ... be the result of a glandular problem or even a ... One common vitamin deficiency is a lack of vitamin ...

(Date:5/20/2013)... 20, 2013 National Community Pharmacists Association ... RPh, MBA issued the following statement today regarding a ... Part D "preferred pharmacy" drug plans , which ... plan,s lowest advertised co-payments: (Logo: http://photos.prnewswire.com/prnh/20100106/DC33253LOGO ... and MedPAC , 16 U.S. Senators ...

Breaking Medicine Technology:Uroplasty To Announce Fiscal Fourth Quarter And Full Year 2013 Financial Results On May 30, 2013 2 USB12Shots.com Discusses the Possibility of B12 Shots for Weight Loss 2 Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 2 Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 3 Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 4

[0] Uroplasty To Announce Fiscal Fourth Quarter And Full Year 2013 Financial Results On May 30, 2013 [0] USB12Shots.com Discusses the Possibility of B12 Shots for Weight Loss [0] Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans

... Nov. 11 WellTek/MedX Group, health, fitness and wellness ... corporate reorganization to facilitate becoming an SEC reporting company. ... Inc. merged into a wholly owned subsidiary of an ... subsequently changed its name to WellTek Incorporated. As ...

... (NYSE: CRY ), an implantable biological medical device ... Anderson, president and chief executive officer of CryoLife, Inc., is ... Annual Healthcare Conference on Wednesday, November 18, 2009 at 1:15 ... may be accessed through its Web site, www.cryolife.com ...

Cached Medicine Technology:WellTek/MedX Group Completes Major Reorganization 2 CryoLife to Present at Upcoming Investor Conferences in New York 2

WellTek/MedX Group Completes Major Reorganization CryoLife to Present at Upcoming Investor Conferences in New York

(Date:5/20/2013)... York, NY (PRWEB) May 20, 2013 ... protecting the rights of victims injured by defective drugs, ... Dakota man who alleges that use of the diabetes ... The suit was filed on April 30, 2013, in ... Louisiana (Case No. 6:13-cv-0888), where it is one of ...

(Date:5/20/2013)... May 20, 2013 According to a May ... at Indoor Tanning Salons,” tanning salons in the ... Food and Drug Administration wants to see cancer warnings on ... minimum age floor of eighteen for the use of indoor ... about melanoma, which has become increasingly common over the last ...

(Date:5/20/2013)... 2013 The Environmental Design ... dozens of continuing education credit opportunities for design ... of Architects Continuing Education System (AIA/CES), the Landscape ... Interior Design Continuing Education Council (IDCEC). EDRA44Providence ... 2013 at the Omni Providence Hotel in Providence, ...

(Date:5/20/2013)... 2013 Co-founder of Atlanta SEO ... keynote speaker at the 5th International INVEST Domaining & ... brings together company representatives and independent individuals from around ... marketing and investments. , The 2013 conference will take ... México from May 20 to 21. A networking city ...

(Date:5/20/2013)... The judge overseeing pretrial proceedings in the federal consolidation ... lawyers to be included in a plaintiffs’ leadership committee, ... the judge’s request, noting that its lawyers can ... Mirena side effects and how to file a lawsuit. ... some female lawyers to the committee. This followed requests ...

Breaking Medicine News(10 mins):Health News:Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man 2 Health News:Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs 2 Health News:Environmental Design Research Conference to Feature AIA/CES, LA CES, and IDCEC Continuing Education Credits 2 Health News:EverSpark CEO to be Keynote Speaker at 5th International INVEST Domaining & Internet Marketing Conference in Mexico City 2 Health News:Mirena IUD Lawsuit Update: Judge Calls for More Input from Female Lawyers, Notes Rottenstein Law Group LLP 2

[0] Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man [0] Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs [0] Environmental Design Research Conference to Feature AIA/CES, LA CES, and IDCEC Continuing Education Credits [0] EverSpark CEO to be Keynote Speaker at 5th International INVEST Domaining & Internet Marketing Conference in Mexico City [0] Mirena IUD Lawsuit Update: Judge Calls for More Input from Female Lawyers, Notes Rottenstein Law Group LLP

... someday help control anxiety, experts say, , , FRIDAY, May 15 ... anxiety isn,t something associated with heights, a job interview or ... state of worry and tension that affects twice as many ... slowly eroding their quality of life. , But a new ...

... ORLANDO A pill used for nerve pain offers women ... 45th Annual Meeting of the American Society of Clinical ... hot flash severity and frequency about 20 percent more than ... the same benefit as gabapentin, an older, related drug, as ...

... in GI and Endoscopy Nursing at SGNA 36th Annual ... Nurses and Associates, Inc. (SGNA) is proud to honor ... awards that recognize their dedication to the field and ... distinguished awards represent the best in GI and endoscopy ...

... Palatin Technologies, Inc. (NYSE Amex: PTN ) announced ... Palatin reported net income of $0.1 million, or $0.00 per basic ... to a net loss of $5.1 million, or $0.06 per basic ... revenues in the quarter ended March 31, 2009 were $5.2 million, ...

... 15 /PRNewswire-Asia-FirstCall/ -- Shengtai,Pharmaceutical, Inc. (OTC Bulletin Board: ... distributor of high-quality, pharmaceutical grade,glucose products in China, ... of fiscal 2009 ended March 31, 2009. , ... has impacted our operations thus far in,fiscal year ...

... Dr. Bruno E. Gerber is recognized in ... is a Consultant Orthopedic Surgeon with a special ... of the lower limbs. He also is employed ... development project regarding innovative orthopedic laser treatment.Dr. Gerber ...

Fear Response May Stem From Protein in Brain Mayo Clinic researchers say agent provides treatment option for women with hot flashes SGNA Honors Outstanding Gastroenterology and Endoscopy Professionals With Nationwide Awards Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results Continental Who's Who Executive Press Release: Dr. Bruno E. Gerber - Medical Professional

... Blind Performance Specimens are intended for ... handling and transportation guidelines, including chain ... Testing Programs regulated by the Substance ... (SAMHSA), Health and Human Services Department ...

Lyphochek® Hemoglobin A1C Linearity Set is a human whole blood based product designed to verify linearity throughout the patient reportable range of hemoglobin A1C assays....

Liquichek Sedimentation Rate Control is a bilevel human whole blood based control designed to monitor both manual and automated methods for measuring erythrocyte sedimentation rates....

Liquichek Reticulocyte Control is a human whole blood based control designed to monitor manual and automated methods for counting reticulocytes. Assayed values are provided at three clinically signif...

Medicine Products:

Blind Performance Specimens Lyphochek Hemoglobin A1C Linearity Set Liquichek Sedimentation Rate Control Liquichek Reticulocyte Control